Core Viewpoint - The National Healthcare Security Administration (NHSA) announced the 2025 version of the National Basic Medical Insurance Drug List and the first Commercial Health Insurance Innovative Drug List, which includes significant updates to enhance drug accessibility for patients [1][2][3]. Group 1: Drug List Adjustments - The new drug list adds 114 new drugs, including 50 innovative drugs, while removing 29 drugs that are either unavailable or can be replaced by others [1][2][3]. - The total number of drugs in the list now stands at 3,253, comprising 1,857 Western medicines and 1,396 traditional Chinese medicines, with improved coverage for critical areas such as cancer, chronic diseases, mental health, rare diseases, and pediatric medications [1][2][3]. Group 2: Financial Implications - The NHSA has assessed the budget impact of new drugs on the medical insurance fund, concluding that the overall financial burden remains manageable within the national budget [3][4][12]. - The introduction of new drugs may lead to increased costs, but many are expected to replace older medications, mitigating the financial impact [3][4][12]. Group 3: Challenges in Hospital Implementation - Despite being included in the insurance list, many "nationally negotiated drugs" face challenges in being adopted by hospitals due to limited capacity in hospital drug lists, which typically accommodate only 1,500 to 2,000 drugs [4][6][8]. - The approval process for new drugs in hospitals can be lengthy, often taking from one to twelve months, which complicates timely access for patients [8][12][44]. Group 4: Dual-Channel Policy - To address the issue of drug availability, the government introduced a "dual-channel" policy, allowing patients to access "nationally negotiated drugs" through designated hospitals and retail pharmacies, ensuring equal reimbursement [14][16][50]. - As of now, 402 nationally negotiated drugs have been integrated into this dual-channel system, significantly increasing sales from under 4 billion yuan in 2020 to nearly 15 billion yuan in 2024 [16][50]. Group 5: Commercial Health Insurance Innovations - The newly established Commercial Health Insurance Innovative Drug List includes 19 drugs, selected from 121 candidates, aimed at covering high-value drugs not included in the basic insurance [27][30][67]. - This list is designed to complement the basic medical insurance system, addressing the gap for high-cost innovative treatments that are crucial for patients with severe conditions [30][32][67]. Group 6: Future Implications - The introduction of the Commercial Health Insurance Innovative Drug List is expected to enhance patient access to high-value treatments, encouraging insurance companies to cover these drugs and potentially increasing patient enrollment in commercial health plans [30][66][73]. - The dual-directory approach aims to create a more robust healthcare financing system, ensuring that patients can access necessary medications while maintaining the sustainability of the insurance funds [30][66][73].

Core Insights - The 2025 version of the National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug Directory has been officially released, adding 114 new drugs, including 50 innovative drugs, while removing 29 drugs that are either not clinically available or can be replaced by better alternatives [1][2] - The total number of drugs in the directory has increased to 3,253, with significant improvements in coverage for key areas such as cancer, chronic diseases, mental health, rare diseases, and pediatric medications [1] - The new directory will be implemented nationwide starting January 1, 2026 [1] Group 1: Drug Inclusion and Economic Impact - The adjustment of the drug directory is a response to public health needs, with the inclusion of innovative and life-saving drugs for conditions like non-small cell lung cancer and cervical cancer [2] - Experts have assessed the budget impact of the new drugs on the medical insurance fund, suggesting that the overall effect will not be significantly detrimental [2] Group 2: Challenges in Hospital Access - Despite the inclusion of "nationally negotiated drugs" in the insurance directory, there are challenges in their availability in hospitals due to limited capacity in hospital drug lists, which typically accommodate only 1,500 to 2,000 drugs [3] - The rapid increase in the number of "nationally negotiated drugs" complicates decisions for hospitals regarding which drugs to include, especially when alternatives already exist [3][4] Group 3: Financial Management and Policy Recommendations - The current budget control system for hospitals means that higher sales of expensive innovative drugs could lead to reduced surpluses or even budget overruns, making hospitals cautious about purchasing "nationally negotiated drugs" [4] - Experts recommend improving incentive mechanisms for the use of "nationally negotiated drugs" and increasing investment in healthcare resources to alleviate financial pressures on hospitals [4] Group 4: Dual-Channel Policy and Payment Innovations - To address the issue of "drugs available in insurance but hard to find in hospitals," a "dual-channel" policy was introduced, allowing patients to access "nationally negotiated drugs" through designated hospitals and retail pharmacies with equal insurance reimbursement [6] - The sales of "nationally negotiated drugs" have significantly increased, from less than 4 billion yuan in 2020 to nearly 15 billion yuan in 2024 [6] - Sichuan Province has implemented a "single payment" policy for high-cost, clinically necessary "nationally negotiated drugs," allowing direct settlement by the insurance fund without affecting hospital budget assessments, thus reducing cost control pressures on hospitals [6]